Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C16G2 Gel and Rinse in Healthy Adults
NCT02044081Phase 2Completed
- Sponsor
- Armata Pharmaceuticals
- Start
- Feb 2014
- Primary completion
- Jul 2014
- Modality
- Antimicrobial Peptides, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of C16G2 in dental caries (4 arms), sponsored by Armata Pharmaceuticals. Primary endpoint: Safety of multiple C16G2 Gel and/or C16G2 Rinse administrations at Day 14. Started Feb 2014; status: completed.
02
Drugs
C16G2
03
Conditions
dental caries
Beyond the preview
Go deeper on NCT02044081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02044081.